Experimental: ALZ-801

DRUG2 trials

Sponsors

Alzheon Inc.

Conditions

Early Alzheimer's Disease

Phase 3

An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

CompletedNCT04770220

Alzheon Inc.Early Alzheimer's Disease

Start: 2021-05-19End: 2024-07-29Updated: 2025-11-07

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects

TerminatedNCT06304883

Alzheon Inc.Early Alzheimer's Disease

Start: 2024-04-02End: 2026-03-11Updated: 2026-06-25

Related Papers

Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial

Drugs2025-09-281 citations

Clinical Pharmacokinetics of Oral ALZ-801/Valiltramiprosate in a 2-Year Phase 2 Trial of APOE4 Carriers with Early Alzheimer’s Disease

Clinical Pharmacokinetics2025-02-052 citations

Phase 3 Trial of Oral Anti‐Amyloid Agent ALZ‐801/Valiltramiprosate in APOE4/4 Homozygotes with Early Alzheimer’s Disease: Baseline Characteristics and Prevalence of Comorbid Cerebral Amyloid Angiopathy

Alzheimer s & Dementia2024-12-01

Effect of an 18-month meditation training on cardiovascular risk in older adults: a secondary analysis of the Age-Well randomized controlled trial.

2024-11-16

Reliability of the assessment of the clinical dementia rating scale from the analysis of medical records in comparison with the reference method.

2024-09-0510 citations

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease

Drugs2024-06-2023 citations